MediGene (MDG1) Given a €19.00 Price Target by Baader Bank Analysts

Baader Bank set a €19.00 ($22.62) target price on MediGene (ETR:MDG1) in a research report sent to investors on Monday. The brokerage currently has a buy rating on the stock.

Separately, Independent Research set a €12.50 ($14.88) target price on MediGene and gave the company a neutral rating in a report on Wednesday, December 6th.

MediGene (ETR:MDG1) opened at €12.66 ($15.07) on Monday. MediGene has a twelve month low of €8.53 ($10.15) and a twelve month high of €15.24 ($18.14).

ILLEGAL ACTIVITY WARNING: This story was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another publication, it was illegally stolen and reposted in violation of US & international copyright legislation. The correct version of this story can be read at

MediGene Company Profile

Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase.

Receive News & Ratings for MediGene AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediGene AG and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit